Home / Mauna Kea Technologies Announces New Clinical Study and Research Collaboration Agreement with the Lung Cancer Initiative at Johnson & Johnson

Mauna Kea Technologies Announces New Clinical Study and Research Collaboration Agreement with the Lung Cancer Initiative at Johnson & Johnson

PARIS & BOSTON, September 20, 2021–(BUSINESS WIRE)–Regulatory News:

Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) (the “Company”), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (“pCLE” and “nCLE”) platform, today announced that it has entered into a new research collaboration agreement with the Lung Cancer Initiative (“LCI”) at Johnson & Johnson1 to advance the validation of Cellvizio as a real-time biopsy guidance tool during robotic-assisted bronchoscopy to potentially reduce the near-miss rate of peripheral lung cancer.

Under the terms of the agreement, Mauna Kea Technologies will participate in a prospective, multi-center, open-label, single-arm clinical feasibility study (the “Study”) led by LCI. The Study will combine nCLE and robotic-assisted bronchoscopy, using both Cellvizio and the Monarch® Platform from Auris Health, Inc., part of the Johnson &…

Read full article…finance.yahoo.com